Enhertu

Enhertu is a medicine used for treating adults with: - HER2-positive breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. HER2-positive means that the cancer cells produce a protein called HER2 in large quantities on their surface, which makes the tumour cells grow more quickly. Enhertu is used on its own in patients who have received one or more HER2-targeted treatments; - HER2-low and HER2-ultralow breast cancer that is metastatic or cannot be removed by surgery. HER2-low and HER2-ultralow means that the cancer cells produce some HER2 on their surface, but less than HER2-positive cancer cells. It is used on its own in patients when the cancer cells have receptors for certain hormones on their surface (HR-positive). It is used in patients who have previously received at least one endocrine therapy (treatment which blocks the effect of oestrogens, a female sex hormone) for metastatic breast cancer and who are not considered for endocrine therapy for their next treatment; - HER2-low breast cancer in patients whose disease is metastatic or cannot be removed by surgery, and who have previously received chemotherapy after the disease had spread or whose disease came back during or within 6 months of treatment following surgery. Enhertu is used on its own; - advanced non-small cell lung cancer (NSCLC) whose cancer cells have a mutation (change) in the gene for the HER2 protein, called an activating HER2 mutation. It is used on its own in patients who had previously been treated with platinum-based chemotherapy with or without immunotherapy (treatment that boosts the immune system’s ability to fight the cancer); - HER2-positive advanced gastric cancer (cancer of the stomach) or gastro-oesophageal junction cancer (cancer at the junction between the stomach and the oesophagus). It is used on its own in patients who have previously received trastuzumab, another HER2-targeted treatment. Enhertu contains the active substance trastuzumab deruxtecan.